TY - JOUR T1 - Hi-C detects genomic structural variants in peripheral blood of pediatric leukemia patients JF - medRxiv DO - 10.1101/2021.10.01.21264442 SP - 2021.10.01.21264442 AU - Claire Mallard AU - Michael J Johnston AU - Anna Bobyn AU - Ana Nikolic AU - Bob Argiropoulos AU - Jennifer A Chan AU - Gregory MT Guilcher AU - Marco Gallo Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/04/2021.10.01.21264442.abstract N2 - B-cell acute lymphoblastic leukemia (B-ALL) is often driven by chromosome translocations that result in recurrent and well-studied gene fusions. Currently, fluorescent in-situ hybridization probes are employed to detect candidate translocations in bone marrow samples from B-ALL patients. Recently Hi-C, a sequencing-based technique originally designed to reconstruct the three-dimensional architecture of the nuclear genome, was shown to effectively recognize structural variants. Here, we demonstrate that Hi-C can be used as a genome-wide assay to detect translocations and other structural variants of potential clinical interest. Structural variants were identified in both bone marrow and peripheral blood samples, including an ETV6-RUNX1 translocation present in one pediatric B-ALL patient. Our report provides proof-of-principle that Hi-C could be an effective strategy to globally detect driver structural variants in B-ALL peripheral blood specimens, reducing the need for invasive bone marrow biopsies and candidate-based clinical tests.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding statement is in the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Collection of all samples was based on written informed consent and their use was approved by the Health Research Ethics Board of Alberta Cancer Committee (certificate number HREBA.CC-18-0169).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll Hi-C datasets generated for this study are available to the community. The processed Hi-C data can be loaded into the WashU Epigenome Browser from the following link: https://wangftp.wustl.edu/hubs/gallo_B-ALL. The raw Hi-C data have been uploaded at the EGA repository (accession number EGAS00001005605). https://wangftp.wustl.edu/hubs/gallo_B-ALL. ER -